單株抗體的全球市場:成長，趨勢，COVID-19的影響，預測(2021年～2026年)

Monoclonal Antibodies Market - Growth, Trends, COVID-19 Impact, and Forecast(2022 - 2027)

出版日期: 2022年01月17日 | 出版商:

Mordor Intelligence Pvt Ltd | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全貌
簡介
目錄

簡介

單株抗體的市場規模，預計在2021年～2026年的預測期間內以8.51％的年複合成長率成長。

單株抗體生產因COVID-19大流行而停止，嚴重影響了全球單株抗體市場，因為廣泛用於癌症和基因治療，影響了全球單株抗體市場。在已開發國家，單株抗體在各治療形式的癌症中變得無處不在，這歸因於全球單株抗體市場的快速成長。與單株抗體相關的成本非常高，因為製造程序複雜，並且由於涉及研發成本，是全球單株抗體市場成長的主要制約因素之一。

本報告提供單株抗體的世界市場調查，市場概要，市場成長要素及阻礙因素分析，市場機會，COVID-19的影響，各製造方法、原料、適應症、終端用戶、地區的市場規模的變化與預測，競爭情形，主要企業的簡介等系統性資訊。

The monoclonal antibody production was halted due to the COVID-19 pandemic, and it severely affected the global monoclonal antibodies market as they are widely used in cancer and gene therapy, thus affecting the global monoclonal antibodies market. Although COVID-19 was at its peak in Europe and the United States in 2020, few companies were working on new therapy based on monoclonal antibodies to treat COVID-19. They isolated the COVID-19 antibodies from a recovered person and tested them as a cure for COVID-19 infection, and they were successful and got approval for emergency use by the United States Food and Drug Administration. For example, in February 2021, the Food and Drug Administration permitted emergency use of combined bamlanivimab and etesevimab therapy developed by Eli Lilly and Company for people with mild to moderate COVID-19 infection. Moreover, due to the potential application of monoclonal antibodies, it can be expected that COVID-19 will promote the global market of monoclonal antibodies.

The monoclonal antibodies are becoming ubiquitous in the treatment of different forms of cancer in developed countries, and this has been attributed to the rapid growth of the global monoclonal antibodies market. According to the report of GOLOBOCAN 2020, there were 19.3 million new cases of cancer and about 10 million deaths due to cancer in the world, and increasing cancer cases are the major growth factor behind the market. The other factors, which may contribute positively toward the high growth of the global monoclonal antibodies market, are new gene-based therapy, new research related to the application of monoclonal antibodies in treating some other deadly diseases, like COVID-19, disease diagnostics, and treatment of other diseases, like auto-immune, viral disease treatment, and also the approval of new antibodies by governments may lead to the growth of the market. For instance, in July 2020, Union Chimique Belge (UCB) did a license agreement with Roche and Genentech for the manufacturing and commercial production of UCB0107, which is a potent monoclonal antibody for the treatment of progressive supranuclear palsy (PSP) and Alzheimer's disease, but it is still under investigation.

The cost associating with monoclonal antibodies is very high because of their complex manufacturing procedure and due to the cost involved in R&D, and it is one of the major restraining factors for the growth of the global monoclonal antibodies market. The high cost of monoclonal antibodies is the main reason why it is still prevalent only in developed countries and not in developing and underdeveloped countries. Another factor responsible that can prove a restraint for this market will be the loss of patents by companies.

Key Market Trends

Cancer Monoclonal Antibodies is Estimated to Occupy a Significant Share in the Market over the Forecast Period

According to the World Health Organization, cancer is the leading cause of death globally. As per the GLOBOCAN 2020 report, there were around 19.3 new cancer cases and about 10 million deaths due to cancer worldwide in 2020, and the most common types of cancer were breast cancer, followed by lung cancer, rectal cancer, prostate cancer, and others. Due to the rising prevalence of cancer cases, globally, in the global monoclonal antibodies market, cancer monoclonal antibodies may occupy a major market share.

Additionally, the global pharmaceutical companies are investing heavily in the R&D of cancer biologics drugs (monoclonal antibodies), because they are very efficient and non-toxic in the diagnostics and treatment of different types of cancer as compared to chemotherapy and other cancer treatment methods. Moreover, getting approvals for many new cancer monoclonal antibodies by the respective governments is more efficient and easy. According to an article published in December 2019 in Taylor & Francis Online, about 5 antibody therapeutics were provided first approval in either European Union or the United States, and these include romosozumab, risankizumab, polatuzumab vedotin, brolucizumab, and crizanlizumab. Polatuzimab vedotin (Polivy) was granted conditional marketing authorization in November 2019 for the treatment of relapsed /refractory diffuse large B-cell lymphoma. In another instance, in December 2020, the United States Food and Drug Administration approved MacroGenics' MARGENZATM for the treatment of patients with pretreated metastatic HER2-positive breast cancer. These advancements may fuel the growth of the monoclonal antibodies market.

North America is Expected to Dominate the Global Monoclonal Antibodies Market during the Forecast Period

North America is segmented into three countries - the United States, Canada, and Mexico. North America may dominate in the market share of global monoclonal antibodies because of the presence of standard nationwide healthcare system, especially in the United States and Canada, huge funding by governments for the R&D of new biological therapies, especially for cancer and new infectious diseases, rising geriatric population and diseases associated with them, and presence of key market players in the region during the forecast period. For example, in November 2020, the Government of Canada and Eli Lilly signed an agreement for a monoclonal antibody therapy called Bamlanivimab (LY-CoV555) for COVID-19 developed by Eli Lilly Company, a total of 26,000 doses were ordered initially.

Some of the key market players are headquartered in the United States, actively advancing the technique, launching new products, and forming strategic partnerships to have an edge in the monoclonal antibodies market. The government's National Institute of Health and other related organizations are also engaged in the development of monoclonal antibodies and, over the year, had few breakthroughs. For instance, in August 2020, the National Institute of Health announced the launch of a clinical trial for two potential treatments of COVID-19 by using monoclonal antibodies. Additionally, the increasing cases of chronic diseases, such as cancer, may boost the growth of the market in the region. As per the GLOBOCAN 2020 report, 2,281,658 new cancer cases were diagnosed and 612,390 deaths due to cancer in the United States alone. The cancer cases in Canada and Mexico were 274,364 and 195,499, respectively. These factors are expected to drive the growth of the studied market over the forecast period.

Competitive Landscape

The global monoclonal antibodies market is expected to be highly competitive with the number of established companies in the market and the new incoming companies, which are investing heavily in R&D with new and advanced technologies. In the current scenario, COVID-19 and cancer therapeutics are expected to be the major domain of competition between the companies. Some of the major key players of the global monoclonal antibodies market are - Eli Lilly, F Hoffmann-La Roche, Merck, Amgen Inc., and Novartis AG, among others.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

1 INTRODUCTION

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
- 4.2.1 Rising Technological Advancements
- 4.2.2 Increasing Burden of Cancer and Other Chronic Diseases
- 4.2.3 Huge Funding by Government for the Research and Development
4.3 Market Restraints
- 4.3.1 High Cost Pertaining to the Method Involved in the Production of Monoclonal Antibodies
- 4.3.2 Loss of Patents
4.4 Industry Attractiveness - Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Buyers/Consumers
- 4.4.2 Bargaining Power of Suppliers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Production Methods
- 5.1.1 In Vivo
- 5.1.2 In Vitro
5.2 By Source
- 5.2.1 Chimeric
- 5.2.2 Human
- 5.2.3 Humanized
- 5.2.4 Murine
5.3 By Indications
- 5.3.1 Cancer
- 5.3.2 Autoimmune Diseases
- 5.3.3 Infectious Diseases
- 5.3.4 Inflammatory Diseases
- 5.3.5 Other Indications
5.4 By End Users
- 5.4.1 Hospitals
- 5.4.2 Research Institutes
- 5.4.3 Other End Users
5.5 By Geography
- 5.5.1 North America
  - 5.5.1.1 United States
  - 5.5.1.2 Canada
  - 5.5.1.3 Mexico
- 5.5.2 Europe
  - 5.5.2.1 Germany
  - 5.5.2.2 United Kingdom
  - 5.5.2.3 France
  - 5.5.2.4 Italy
  - 5.5.2.5 Spain
  - 5.5.2.6 Rest of Europe
- 5.5.3 Asia Pacific
  - 5.5.3.1 China
  - 5.5.3.2 Japan
  - 5.5.3.3 India
  - 5.5.3.4 Australia
  - 5.5.3.5 South Korea
  - 5.5.3.6 Rest of Asia Pacific
- 5.5.4 Middle-East and Africa
  - 5.5.4.1 GCC
  - 5.5.4.2 South Africa
  - 5.5.4.3 Rest of Middle-East and Africa
- 5.5.5 South America
  - 5.5.5.1 Brazil
  - 5.5.5.2 Argentina
  - 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles
- 6.1.1 Eli Lilly and Company
- 6.1.2 Johnson & Johnson
- 6.1.3 Merck KGaA
- 6.1.4 Pfizer Inc.
- 6.1.5 GlaxoSmithKline PLC
- 6.1.6 Novartis AG
- 6.1.7 AstraZeneca PLC
- 6.1.8 Amgen Inc.
- 6.1.9 AbbVie Inc.
- 6.1.10 Bristol Myers Squibb Co.